Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.86%
EBIT Growth (5y)
94.78%
EBIT to Interest (avg)
28.62
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.23
Tax Ratio
13.17%
Dividend Payout Ratio
24.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.46%
ROE (avg)
7.05%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.66
EV to EBIT
20.45
EV to EBITDA
16.88
EV to Capital Employed
3.28
EV to Sales
5.97
PEG Ratio
NA
Dividend Yield
3.28%
ROCE (Latest)
16.05%
ROE (Latest)
11.34%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CHF 150.98 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 3.61%
-12What is not working for the Company
INTEREST(HY)
At CHF 0.09 MM has Grown at 68.37%
NET SALES(Q)
At CHF 48.7 MM has Fallen at -62.82%
PRE-TAX PROFIT(Q)
At CHF -2.93 MM has Fallen at -103.82%
NET PROFIT(Q)
At CHF -4.19 MM has Fallen at -106.17%
RAW MATERIAL COST(Y)
Grown by 11.15% (YoY
OPERATING PROFIT(Q)
Lowest at CHF 0.14 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 0.29 %
Here's what is working for Cosmo Pharmaceuticals NV
Operating Cash Flow
Highest at CHF 150.98 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CHF MM)
Inventory Turnover Ratio
Highest at 3.61% and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Depreciation
At CHF 5.9 MM has Grown at 25.15%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (CHF MM)
Here's what is not working for Cosmo Pharmaceuticals NV
Interest
At CHF 0.09 MM has Grown at 68.37%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CHF MM)
Net Sales
At CHF 48.7 MM has Fallen at -62.82%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (CHF MM)
Pre-Tax Profit
At CHF -2.93 MM has Fallen at -103.82%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CHF MM)
Net Profit
At CHF -4.19 MM has Fallen at -106.17%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CHF MM)
Operating Profit
Lowest at CHF 0.14 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CHF MM)
Operating Profit Margin
Lowest at 0.29 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Raw Material Cost
Grown by 11.15% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
